Copyright ©The Author(s) 2015.
World J Hematol. Aug 6, 2015; 4(3): 16-53
Published online Aug 6, 2015. doi: 10.5315/wjh.v4.i3.16
Figure 10
Figure 10 Charaterization of polycythemia vera study group defined essential thrombocythemia and polycythemia vera by applying the 2006 European Clinical Molecular and Pathological criteria and 2001 World Health Organization bone marrow features; JAK2V617F mutated normocellular essential thrombocythemia, prodromal polycythemia vera, classical polycythemia vera and myelofibrosis vs JAK2 wild type normocelluar essential thrombocythemia and chronic idiopathic myelofibrosis or Primary megakaryocytic granulocytic myeloproliferation. WHO: World Health Organization; PV: Polycythemia vera; ECMP: European clinical molecular and pathological; MF: Myelofibrosis; ET: Essential thrombocythemia; MPN: Myeloproliferative neoplasm; PMGM: Primary megakaryocytic granulocytic myeloproliferation; PVSG: Polycythemia vera study group; CALR: Calreticulin.